Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical models of non-alcoholic fatty liver disease
Prasanna K. Santhekadur, Divya P. Kumar, Arun J. Sanyal
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 230-237
Open Access | Times Cited: 328

Showing 1-25 of 328 citing articles:

Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander‐Tetri, Mary E. Rinella, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 908-922
Open Access | Times Cited: 3251
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Mohammed Eslam, Arun J. Sanyal, Jacob George, et al.
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1999-2014.e1
Open Access | Times Cited: 2561
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
David Højland Ipsen, Jens Lykkesfeldt, Pernille Tveden‐Nyborg
Cellular and Molecular Life Sciences (2018) Vol. 75, Iss. 18, pp. 3313-3327
Open Access | Times Cited: 1095
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 731
Past, present and future perspectives in nonalcoholic fatty liver disease
Arun J. Sanyal
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 6, pp. 377-386
Closed Access | Times Cited: 458
Cell Death in Liver Diseases: A Review
Layla Shojaie, Andrea Iorga, Lily Dara
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9682-9682
Open Access | Times Cited: 212
The ménage à trois of autophagy, lipid droplets and liver disease
Yasmina Filali-Mouncef, Catherine J. Hunter, Federica Roccio, et al.
Autophagy (2021) Vol. 18, Iss. 1, pp. 50-72
Open Access | Times Cited: 210
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Zachary J. Brown, Bernd Heinrich, Tim F. Greten
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 15, Iss. 9, pp. 536-554
Closed Access | Times Cited: 202
Animal models for liver disease – A practical approach for translational research
Yulia A. Nevzorova, Zoé Boyer-Díaz, Francisco Javier Cubero, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 423-440
Open Access | Times Cited: 189
Animal models of NAFLD from a hepatologist's point of view
Daniel Jahn, Stefan Kircher, Heike M. Hermanns, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2018) Vol. 1865, Iss. 5, pp. 943-953
Open Access | Times Cited: 169
MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway
Tianpeng Zhang, Junjie Hu, Xiaomei Wang, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 1, pp. 87-96
Open Access | Times Cited: 168
A researcher’s guide to preclinical mouse NASH models
Suchira Gallage, Jose Efren Barragan Avila, Pierluigi Ramadori, et al.
Nature Metabolism (2022) Vol. 4, Iss. 12, pp. 1632-1649
Closed Access | Times Cited: 101
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder, et al.
Nature Metabolism (2024) Vol. 6, Iss. 6, pp. 1178-1196
Open Access | Times Cited: 53
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 50
Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
Alessandro Cherubini, Sara Della Torre, Serena Pelusi, et al.
Trends in Molecular Medicine (2024)
Closed Access | Times Cited: 14
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yao Yu, Jingjing Cai, Zhi‐Gang She, et al.
Advanced Science (2018) Vol. 6, Iss. 4
Open Access | Times Cited: 149
A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis
Adel Hammoutène, Louise Biquard, Juliette Lasselin, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 3, pp. 528-538
Open Access | Times Cited: 139
Progress and challenges in the prevention and control of nonalcoholic fatty liver disease
Jingjing Cai, Xiao‐Jing Zhang, Hongliang Li
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 328-348
Open Access | Times Cited: 130
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
Eun Hee Koh, Ji Eun Yoon, Myoung Seok Ko, et al.
Gut (2020) Vol. 70, Iss. 10, pp. 1954-1964
Open Access | Times Cited: 122
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
Clémence Rives, Anne Fougerat, Sandrine Ellero‐Simatos, et al.
Biomolecules (2020) Vol. 10, Iss. 12, pp. 1702-1702
Open Access | Times Cited: 116
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Joost Boeckmans, Alessandra Natale, Matthias Rombaut, et al.
Cells (2019) Vol. 9, Iss. 1, pp. 37-37
Open Access | Times Cited: 109
Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system
Mengting Chen, Pengfei Hou, Min Zhou, et al.
Clinical Nutrition (2019) Vol. 39, Iss. 4, pp. 1264-1275
Closed Access | Times Cited: 99
Rodent Models of Nonalcoholic Fatty Liver Disease
Fang Zhong, Xiaoming Zhou, Jin Xu, et al.
Digestion (2019) Vol. 101, Iss. 5, pp. 522-535
Open Access | Times Cited: 97
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Pierre‐Antoine Soret, Julie Magusto, Chantal Housset, et al.
Journal of Clinical Medicine (2020) Vol. 10, Iss. 1, pp. 36-36
Open Access | Times Cited: 95
Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]
José C. Fernández-Checa, Pierre Bagnaninchi, Hui Ye, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 935-959
Open Access | Times Cited: 88
Page 1 - Next Page

Scroll to top